Vanda begins phase 3 trial of antipsychotic agent iloperidone licensed from Titan

By E. Janene Geiss

Philadelphia, Dec. 12 - Titan Pharmaceuticals, Inc. announced Monday that Vanda Pharmaceuticals Inc. has begun a phase 3 clinical study of iloperidone, Titan's proprietary antipsychotic agent licensed to Vanda and in development for the treatment of schizophrenia and related disorders.

The study is designed as a randomized, double-blind, controlled, three-arm study. Patients in this multi-center study will receive iloperidone, placebo or an active control, according to a company news release.

The study is designed to assess the efficacy, safety and tolerability of iloperidone in schizophrenic patients in acute exacerbation. The primary endpoint of the study is the reduction in the symptoms of schizophrenia as assessed by the Positive and Negative Symptom Scale.

Iloperidone is a novel 5HT2/D2 antagonist, antipsychotic agent in development for schizophrenia and other disorders, officials said.

Titan Pharmaceuticals is a South San Francisco, Calif., biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system disorders, cardiovascular disease, bone disease and other disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.